# A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma

Source: https://onco.cc/trials/nct06566586/  
OnCo record `nct06566586` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of TQB3702 tablets+Chemotherapy regimen in non-Hodgkin lymphoma, run by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., now recruiting.

## Summary

A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma is a phase 2 interventional study registered as NCT06566586 by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., with 80 participants planned, started 2024-11-06 and due to reach its primary completion in 2026-03. Interventions recorded: TQB3702 tablets+Chemotherapy regimen.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06566586
- Phase: 2
- Setting: A Phase II Clinical Trial to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma
- Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Enrolled: 80

## Sources

- ClinicalTrials.gov NCT06566586: https://clinicaltrials.gov/study/NCT06566586

## Connected records

- cancers: [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- companies: [Sino Biopharmaceutical (Chia Tai Tianqing)](https://onco.cc/companies/sino-biopharm/)
- drugs: [TQB3702](https://onco.cc/drugs/tqb3702/)

---
JSON: https://onco.cc/api/v1/entities/nct06566586.json